NETWORK DRIVE EXECUTIVE SUMMARY
The purpose of this Confidential Investment Offering Overview is to provide a summary of a possible future private investment opportunity that may be made available to a certain limited number of accredited investors. This is not an offer to sell real estate and/or any type of security, partnership interest, public or otherwise.
The contemplated offering, if made available formally, would provide investors with the opportunity to acquire a partial interest in a 7,475 square foot medical office facility, located in Plainfield (Suburban Indianapolis), Indiana. The building and property are 100% net leased to DSI Renal, Inc, a wholly owned subsidiary of DaVita, Inc., a Fortune 500 company, which is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and End Stage Renal Disease (ESRD). DSI Renal, based in Nashville, runs 106 dialysis centers across the country serving over 8,000 patients.
A summary of the key investment highlights follows:
• 15 year net lease with 12 years remaining.
• December, 2010 revenues of nearly $6.5 billion with shareholder’s equity of approximately $1.88 billion.
DSI Renal, Inc. was formed in 2006 with 106 dialysis centers across the nation. DSI Renal, which had annualized revenue of approximately $360 million, was purchased in September, 2011 by DaVita for $690 million, or approximately $6.5 million per location. DSI Renal is now a wholly owned subsidiary of Davita, which provides administrative services to 1,612 outpatient dialysis centers, located in 43 states and serving approximately 125,000 patients, as well as provides acute inpatient dialysis services in nearly 750 hospitals. DaVita is one of the largest kidney care companies in the United States. Their offerings include in-center hemodialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance. The company also operates or provides management and administrative services to 32 outpatient dialysis centers in which it either owns a minority equity investment or which are wholly-owned by third parties. In addition, the company offers infusion therapy services; DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; vascular access services; disease management services and special needs plans; physician services; and clinical research programs. DaVita was rated by Fortune Magazine as one of the top 10 most admired healthcare companies in the United States for the 5th year in a row.
DaVita is headquartered in Denver, Colorado and employs over 36,000 people throughout their various divisions across the country. DaVita was rated 359 on the list of the 500 largest corporations published by “Fortune Magazine” in 2011.
DaVita, Inc. is a publicly traded company on the New York Stock Exchange, under the ticker symbol DVA. The company generated revenues of approximately $6.44 billion for the year ending December 31, 2010, with a net income of $405 million. The company reported a shareholder’s equity of approximately $1.88 billion as of June 30, 2011. DaVita is rated BB-/Stable by Standard and Poors. More information regarding DaVita can be found in Exhibits B and E as well as by visiting www.davita.com